2-((3R,4S)-3-methylpiperidin-4-yl)ethanoic acid ethyl ester | 190444-21-4

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 2-((3R,4S)-3-methylpiperidin-4-yl)ethanoic acid ethyl ester
• 英文别名: cis-3(R)-methyl-4(S)-piperidineacetic acid ethyl ester；ethyl 2-((3R,4S)-3-methylpiperidin-4-yl)acetate；ethyl 2-[(3R,4S)-3-methylpiperidin-4-yl]acetate
• CAS: 190444-21-4
• 化学式: C₁₀H₁₉NO₂
• 分子量: 185.266
• InChiKey: PUEZACXRXDUMTB-IUCAKERBSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  13
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.9
• 拓扑面积：
  38.3
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1-[bis(4-fluorophenyl)methoxy]-4-chlorobutane 、 2-((3R,4S)-3-methylpiperidin-4-yl)ethanoic acid ethyl ester 在 potassium carbonate 、 sodium iodide 作用下， 以 乙腈 为溶剂， 反应 24.0h， 以66%的产率得到ethyl 2-[(3R,4S)-1-[4-[bis(4-fluorophenyl)methoxy]butyl]-3-methylpiperidin-4-yl]acetate
  参考文献：
  名称：

  New N-(benzhydryloxyalkyl)-4-(carboxy/carbamoylmethyl) piperidine derivatives with antidepressant activity

  摘要：

  Several benzhydryloxylalkylpiperidine derivatives were prepared with the aim of obtaining new antidepressant compounds. The influence of the length of the aliphatic chain and of aromatic and piperidine ring substitutions was studied. The pharmacological activity of compounds was investigated in vivo by means of a screening comprising four pharmacological tests: antagonism of reserpine and apomorphine hypothermia; increase of yohimbine induced mortality; and antagonism of immobility in tail suspension test. An in-depth pharmacological study was performed with the more active compounds and a binding study to serotonin (5-HT), norepinephrine (NE) and dopamine (DA) reuptake sites was performed for the preferred compounds. The most active compounds [+], [-]-cis-31, 32 and 46 exhibited an interesting psychopharmacological profile after intraperitoneal administration. This profile was confirmed by the oral route for 31 and 46. In vitro, these compounds showed a non-selective inhibition of DA, NE and 5-HT uptake.

  DOI：

  10.1016/s0223-5234(97)83972-4
• 作为产物：
  描述：

  (3-methylpiperidin-4-yl)acetic acid ethyl ester 以6.18%的产率得到2-((3R,4S)-3-methylpiperidin-4-yl)ethanoic acid ethyl ester
  参考文献：
  名称：

  New N-(benzhydryloxyalkyl)-4-(carboxy/carbamoylmethyl) piperidine derivatives with antidepressant activity

  摘要：

  Several benzhydryloxylalkylpiperidine derivatives were prepared with the aim of obtaining new antidepressant compounds. The influence of the length of the aliphatic chain and of aromatic and piperidine ring substitutions was studied. The pharmacological activity of compounds was investigated in vivo by means of a screening comprising four pharmacological tests: antagonism of reserpine and apomorphine hypothermia; increase of yohimbine induced mortality; and antagonism of immobility in tail suspension test. An in-depth pharmacological study was performed with the more active compounds and a binding study to serotonin (5-HT), norepinephrine (NE) and dopamine (DA) reuptake sites was performed for the preferred compounds. The most active compounds [+], [-]-cis-31, 32 and 46 exhibited an interesting psychopharmacological profile after intraperitoneal administration. This profile was confirmed by the oral route for 31 and 46. In vitro, these compounds showed a non-selective inhibition of DA, NE and 5-HT uptake.

  DOI：

  10.1016/s0223-5234(97)83972-4

文献信息

• NUCLEAR RECEPTOR MODULATORS (ROR) FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES
  申请人：AbbVie Inc.

  公开号：EP3636643A1

  公开（公告）日：2020-04-15

  The invention provides compounds of the following formula, pharmaceutically acceptable salts thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological conditions.

  本发明提供了下式化合物及其药学上可接受的盐类，其中变量在此定义。本发明的化合物可用于治疗免疫学疾病。
• Nuclear receptor modulators
  申请人：AbbVie Inc.

  公开号：US10106501B2

  公开（公告）日：2018-10-23

  The invention provides compounds of Formula (I) pharmaceutically acceptable salts, thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological conditions.

  本发明提供了式 (I) 的化合物 其药学上可接受的盐类，其中变量在本文中定义。本发明的化合物可用于治疗免疫学疾病。
• NUCLEAR RECEPTOR MODULATORS
  申请人：AbbVie Inc.

  公开号：EP3307734A1

  公开（公告）日：2018-04-18
• [EN] NUCLEAR RECEPTOR MODULATORS<br/>[FR] MODULATEURS DES RÉCEPTEURS NUCLÉAIRES
  申请人：ABBVIE INC

  公开号：WO2016200851A1

  公开（公告）日：2016-12-15

  The invention provides compounds of Formula (I), pharmaceutically acceptable salts, thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological conditions.
• New N-(benzhydryloxyalkyl)-4-(carboxy/carbamoylmethyl) piperidine derivatives with antidepressant activity
  作者：Y El Ahmad、P Maillet、E Laurent、A Talab、JF Teste、MJ Cédat、PY Fiez-Vandal、R Dokhan、R Ollivier

  DOI：10.1016/s0223-5234(97)83972-4

  日期：1997.1

  Several benzhydryloxylalkylpiperidine derivatives were prepared with the aim of obtaining new antidepressant compounds. The influence of the length of the aliphatic chain and of aromatic and piperidine ring substitutions was studied. The pharmacological activity of compounds was investigated in vivo by means of a screening comprising four pharmacological tests: antagonism of reserpine and apomorphine hypothermia; increase of yohimbine induced mortality; and antagonism of immobility in tail suspension test. An in-depth pharmacological study was performed with the more active compounds and a binding study to serotonin (5-HT), norepinephrine (NE) and dopamine (DA) reuptake sites was performed for the preferred compounds. The most active compounds [+], [-]-cis-31, 32 and 46 exhibited an interesting psychopharmacological profile after intraperitoneal administration. This profile was confirmed by the oral route for 31 and 46. In vitro, these compounds showed a non-selective inhibition of DA, NE and 5-HT uptake.